Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 21, 2026, 5:52 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 355 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Overactive Bladder Clear all
Not listed Phase 4 Interventional
View directory record Official record
Conditions
Urinary Bladder, Overactive, Pelvic Organ Prolapse
Interventions
OnabotulinumtoxinA 100 UNT, Injectable saline
Drug · Other
Lead sponsor
Walter Reed National Military Medical Center
Federal
Eligibility
18 Years and older · Female only
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 13, 2021 · Synced May 21, 2026, 5:52 PM EDT
Completed Phase 4 Interventional Results available
View directory record Official record
Conditions
Urinary Bladder, Overactive
Interventions
Fesoterodine 8 mg, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
990 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
109
States / cities
Birmingham, Alabama • Fairhope, Alabama • Chandler, Arizona + 80 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2018 · Synced May 21, 2026, 5:52 PM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Overactive Bladder
Interventions
Solabegron modified release tablets, low dose, Solabegron modified release tablets, high dose, Matching Placebo
Drug
Lead sponsor
Velicept Therapeutics, Inc.
Industry
Eligibility
18 Years to 80 Years · Female only
Enrollment
1,413 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
77
States / cities
Birmingham, Alabama • Guntersville, Alabama • Saraland, Alabama + 61 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2020 · Synced May 21, 2026, 5:52 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers
View directory record Official record
Conditions
Overactive Bladder, Caffeine, Menopause
Interventions
400 mg of caffeine/day (Two 200mg pills/day), 200 mg of caffeine/day (One 200mg pill and one placebo pill), Two placebo pills/day
Dietary Supplement
Lead sponsor
Loma Linda University
Other
Eligibility
58 Years and older · Female only
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Oct 24, 2018 · Synced May 21, 2026, 5:52 PM EDT
Completed Not applicable Interventional
View directory record Official record
Conditions
Overactive Bladder (OAB)
Interventions
FemPulse System
Device
Lead sponsor
FemPulse Corporation
Industry
Eligibility
21 Years and older · Female only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Fort Lauderdale, Florida
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced May 21, 2026, 5:52 PM EDT
Completed Phase 4 Interventional Results available
View directory record Official record
Conditions
Overactive Bladder in Parkinson's Disease
Interventions
solifenacin succinate (VESIcare), placebo
Drug
Lead sponsor
University of South Florida
Other
Eligibility
40 Years to 80 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
3
States / cities
Miami, Florida • Tampa, Florida • Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 8, 2021 · Synced May 21, 2026, 5:52 PM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Urinary Bladder Overactive, Overactive Bladder, Urgency Incontinence, Urinary Bladder Diseases\Urologic Diseases
Interventions
Solifenacin succinate, Mirabegron, Placebo to match solifenacin, Placebo to match mirabegron
Drug
Lead sponsor
Astellas Pharma Europe B.V.
Industry
Eligibility
18 Years and older
Enrollment
1,829 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
75
States / cities
Mobile, Alabama • Chandler, Arizona • Phoenix, Arizona + 61 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2024 · Synced May 21, 2026, 5:52 PM EDT
Completed Phase 4 Interventional
View directory record Official record
Conditions
Urinary Incontinence
Interventions
Darifenacin, Behavioral therapy
Drug · Behavioral
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
395 participants
Timeline
2005 – 2006
U.S. locations
67
States / cities
Birmingham, Alabama • Tucson, Arizona • Culver City, California + 58 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2008 · Synced May 21, 2026, 5:52 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers
View directory record Official record
Conditions
Healthy Subjects, Pharmacokinetics of YM178
Interventions
YM178 OCAS, Ketoconazole
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
19 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Aug 31, 2015 · Synced May 21, 2026, 5:52 PM EDT
Completed Phase 1Phase 2 Interventional Results available
View directory record Official record
Conditions
Overactive Bladder, Detrusor Instability, Detrusor Hyperreflexia
Interventions
Botulinum-A toxin, Dimethyl sulfoxide (DMSO)
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 20, 2014 · Synced May 21, 2026, 5:52 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available
View directory record Official record
Conditions
Overactive Bladder
Interventions
Mirabegron 50 MG, Posterior Tibial Nerve Stimulation (PTNS)
Drug · Device
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older · Female only
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jul 19, 2023 · Synced May 21, 2026, 5:52 PM EDT
Completed Phase 3 Interventional
View directory record Official record
Conditions
Overactive Bladder Syndrome
Interventions
Darifenacin, Placebo
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
445 participants
Timeline
2004
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 22, 2008 · Synced May 21, 2026, 5:52 PM EDT
Recruiting Not applicable Interventional
View directory record Official record
Conditions
Urology, Urinary Bladder, Overactive, Benign Prostatic Hyperplasia, Urodynamics, Home Monitoring, Urinary Incontinence (UI), Lower Urinary Tract Dysfunction
Interventions
Glean Urodynamics System
Device
Lead sponsor
Bright Uro
Industry
Eligibility
22 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
7
States / cities
Hanover, Maryland • Owings Mills, Maryland • St Louis, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced May 21, 2026, 5:52 PM EDT
Terminated Not applicable Interventional
View directory record Official record
Conditions
Urinary Bladder, Overactive, Urinary Incontinence, Urge
Interventions
Overactive Bladder Care Plan counseling
Other
Lead sponsor
Hartford Hospital
Other
Eligibility
18 Years to 89 Years · Female only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
3
States / cities
Glastonbury, Connecticut • Hartford, Connecticut • West Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 30, 2015 · Synced May 21, 2026, 5:52 PM EDT
Completed Not applicable Interventional
View directory record Official record
Conditions
Stress Urinary Incontinence, Urge Incontinence, Urge and Stress, Overactive Bladder
Interventions
BTL EMSELLA Active treatment, BTL EMSELLA Sham Treatment
Device
Lead sponsor
Boston Urogynecology Associates
Other
Eligibility
18 Years to 100 Years · Female only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 4, 2025 · Synced May 21, 2026, 5:52 PM EDT
Terminated Phase 2 Interventional
View directory record Official record
Conditions
Incontinence, Urinary and Urinary Bladder, Overactive, Overactive Bladder
Interventions
GW679769
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
3
States / cities
Long Beach, California • Cleveland, Ohio • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 16, 2015 · Synced May 21, 2026, 5:52 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available
View directory record Official record
Conditions
Overactive Bladder, Urge Incontinence, Fecal Incontinence
Interventions
Lidocaine patch, Placebo
Drug · Other
Lead sponsor
University of Louisville
Other
Eligibility
18 Years and older · Female only
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
2
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Feb 2, 2025 · Synced May 21, 2026, 5:52 PM EDT
Enrolling by invitation Not applicable Interventional
View directory record Official record
Conditions
Overactive Bladder Syndrome
Interventions
Device Morpheus8V
Device
Lead sponsor
InMode MD Ltd.
Industry
Eligibility
21 Years to 80 Years · Female only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
Corona del Mar, California • Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 17, 2025 · Synced May 21, 2026, 5:52 PM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Overactive Bladder
Interventions
Tolterodine ER, Placebo, Fesoterodine
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
2,417 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
102
States / cities
Enterprise, Alabama • Mobile, Alabama • Montgomery, Alabama + 85 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2011 · Synced May 21, 2026, 5:52 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Endometriosis Related Pain, Overactive Bladder, Diabetic Neuropathic Pain, Refractory or Unexplained Chronic Cough
Interventions
BAY1817080, Midazolam
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 79 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
2
States / cities
Miami, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jan 19, 2023 · Synced May 21, 2026, 5:52 PM EDT
Terminated Not applicable Interventional
View directory record Official record
Conditions
Electrical Evaluation of Urinary Bladder
Interventions
Electrical mapping of the urinary bladder
Procedure
Lead sponsor
Englewood Hospital and Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Englewood, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 2, 2016 · Synced May 21, 2026, 5:52 PM EDT
Withdrawn Phase 4 Interventional
View directory record Official record
Conditions
Urinary Frequency/Urgency, Bladder Irritable, Bladder Pain Syndrome
Interventions
Mirabegron
Drug
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
18 Years to 89 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Oct 21, 2020 · Synced May 21, 2026, 5:52 PM EDT
Completed Phase 1 Interventional Results available
View directory record Official record
Conditions
Overactive Bladder Syndrome
Interventions
V117957, Placebo
Drug
Lead sponsor
Imbrium Therapeutics
Industry
Eligibility
18 Years to 70 Years · Female only
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
12
States / cities
Tucson, Arizona • Canoga Park, California • Long Beach, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2025 · Synced May 21, 2026, 5:52 PM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Heart Failure, Overactive Bladder, Incontinence
Interventions
Extended release torsemide, Immediate release torsemide, Extended release torsemide placebo, Immediate release torsemide placebo
Drug
Lead sponsor
Sarfez Pharmaceuticals, Inc.
Industry
Eligibility
50 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced May 21, 2026, 5:52 PM EDT